JP2011525898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011525898A5 JP2011525898A5 JP2011515594A JP2011515594A JP2011525898A5 JP 2011525898 A5 JP2011525898 A5 JP 2011525898A5 JP 2011515594 A JP2011515594 A JP 2011515594A JP 2011515594 A JP2011515594 A JP 2011515594A JP 2011525898 A5 JP2011525898 A5 JP 2011525898A5
- Authority
- JP
- Japan
- Prior art keywords
- ylmethyl
- triazolo
- amine
- pyrid
- pyrimidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 5-methyl-furan-2-yl Chemical group 0.000 claims description 27
- 150000001875 compounds Chemical class 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 22
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 208000035475 disorder Diseases 0.000 claims description 13
- 208000016285 Movement disease Diseases 0.000 claims description 12
- 208000018737 Parkinson disease Diseases 0.000 claims description 12
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 125000003545 alkoxy group Chemical group 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 239000012453 solvate Substances 0.000 claims description 10
- 206010034010 Parkinsonism Diseases 0.000 claims description 9
- 102000005962 receptors Human genes 0.000 claims description 9
- 108020003175 receptors Proteins 0.000 claims description 9
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 8
- 229960005305 adenosine Drugs 0.000 claims description 8
- 208000026139 Memory disease Diseases 0.000 claims description 6
- 208000002193 Pain Diseases 0.000 claims description 6
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 6
- 102000000033 Purinergic Receptors Human genes 0.000 claims description 6
- 108010080192 Purinergic Receptors Proteins 0.000 claims description 6
- 208000010877 cognitive disease Diseases 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 6
- 125000001072 heteroaryl group Chemical group 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
- FVLAYJRLBLHIPV-UHFFFAOYSA-N pyrimidin-5-amine Chemical compound NC1=CN=CN=C1 FVLAYJRLBLHIPV-UHFFFAOYSA-N 0.000 claims description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 4
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000003118 aryl group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 229920006395 saturated elastomer Polymers 0.000 claims description 4
- 208000024827 Alzheimer disease Diseases 0.000 claims description 3
- 206010003694 Atrophy Diseases 0.000 claims description 3
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 3
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 3
- 208000000094 Chronic Pain Diseases 0.000 claims description 3
- 102000012437 Copper-Transporting ATPases Human genes 0.000 claims description 3
- 206010012335 Dependence Diseases 0.000 claims description 3
- 208000002603 Dopa-responsive dystonia Diseases 0.000 claims description 3
- 208000002972 Hepatolenticular Degeneration Diseases 0.000 claims description 3
- 208000023105 Huntington disease Diseases 0.000 claims description 3
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 3
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 3
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 3
- 208000008238 Muscle Spasticity Diseases 0.000 claims description 3
- 208000002033 Myoclonus Diseases 0.000 claims description 3
- 208000036757 Postencephalitic parkinsonism Diseases 0.000 claims description 3
- 208000005793 Restless legs syndrome Diseases 0.000 claims description 3
- 208000018839 Wilson disease Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 3
- 208000005298 acute pain Diseases 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 3
- 230000037444 atrophy Effects 0.000 claims description 3
- 210000004227 basal ganglia Anatomy 0.000 claims description 3
- 230000000903 blocking effect Effects 0.000 claims description 3
- 210000000133 brain stem Anatomy 0.000 claims description 3
- 230000007850 degeneration Effects 0.000 claims description 3
- 201000010099 disease Diseases 0.000 claims description 3
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 3
- 210000000609 ganglia Anatomy 0.000 claims description 3
- 201000003631 narcolepsy Diseases 0.000 claims description 3
- 230000001898 pallidal effect Effects 0.000 claims description 3
- 208000023515 periodic limb movement disease Diseases 0.000 claims description 3
- 208000000170 postencephalitic Parkinson disease Diseases 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 3
- 229930195734 saturated hydrocarbon Natural products 0.000 claims description 3
- 208000018198 spasticity Diseases 0.000 claims description 3
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- SRRFCARXXFSCSB-UHFFFAOYSA-N 1-[6-[(5-amino-7-phenyltriazolo[4,5-d]pyrimidin-3-yl)methyl]pyridin-2-yl]cyclobutan-1-ol Chemical compound C=12N=NN(CC=3N=C(C=CC=3)C3(O)CCC3)C2=NC(N)=NC=1C1=CC=CC=C1 SRRFCARXXFSCSB-UHFFFAOYSA-N 0.000 claims description 2
- XNXGMIGCARIDKO-UHFFFAOYSA-N 1-[6-[(5-amino-7-phenyltriazolo[4,5-d]pyrimidin-3-yl)methyl]pyridin-2-yl]cyclopentan-1-ol Chemical compound C=12N=NN(CC=3N=C(C=CC=3)C3(O)CCCC3)C2=NC(N)=NC=1C1=CC=CC=C1 XNXGMIGCARIDKO-UHFFFAOYSA-N 0.000 claims description 2
- ZCIMLPGZYISKTM-UHFFFAOYSA-N 1-[6-[[5-amino-7-(3-methoxyphenyl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]cyclobutan-1-ol Chemical compound COC1=CC=CC(C=2C=3N=NN(CC=4N=C(C=CC=4)C4(O)CCC4)C=3N=C(N)N=2)=C1 ZCIMLPGZYISKTM-UHFFFAOYSA-N 0.000 claims description 2
- NCBRBZZVSUEOFQ-UHFFFAOYSA-N 1-[6-[[5-amino-7-(4-methyl-1,3-thiazol-2-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]cyclopentan-1-ol Chemical compound CC1=CSC(C=2C=3N=NN(CC=4N=C(C=CC=4)C4(O)CCCC4)C=3N=C(N)N=2)=N1 NCBRBZZVSUEOFQ-UHFFFAOYSA-N 0.000 claims description 2
- PGCTZXXIHHZPHM-UHFFFAOYSA-N 1-[6-[[5-amino-7-(5-methylfuran-2-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]cyclobutan-1-ol Chemical compound O1C(C)=CC=C1C1=NC(N)=NC2=C1N=NN2CC1=CC=CC(C2(O)CCC2)=N1 PGCTZXXIHHZPHM-UHFFFAOYSA-N 0.000 claims description 2
- MSIICSVPSIMRKM-UHFFFAOYSA-N 1-[6-[[5-amino-7-(5-methylfuran-2-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]cyclohexan-1-ol Chemical compound O1C(C)=CC=C1C1=NC(N)=NC2=C1N=NN2CC1=CC=CC(C2(O)CCCCC2)=N1 MSIICSVPSIMRKM-UHFFFAOYSA-N 0.000 claims description 2
- WRQYDKYVNGEQCW-UHFFFAOYSA-N 1-[6-[[5-amino-7-(5-methylfuran-2-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]cyclopentan-1-ol Chemical compound O1C(C)=CC=C1C1=NC(N)=NC2=C1N=NN2CC1=CC=CC(C2(O)CCCC2)=N1 WRQYDKYVNGEQCW-UHFFFAOYSA-N 0.000 claims description 2
- XXDKXHMRTBKSFA-UHFFFAOYSA-N 2-[6-[(5-amino-7-phenyltriazolo[4,5-d]pyrimidin-3-yl)methyl]pyridin-2-yl]propan-2-ol Chemical compound CC(C)(O)C1=CC=CC(CN2C3=NC(N)=NC(=C3N=N2)C=2C=CC=CC=2)=N1 XXDKXHMRTBKSFA-UHFFFAOYSA-N 0.000 claims description 2
- WBQDITDDICQDQQ-UHFFFAOYSA-N 2-[6-[[5-amino-7-(3-methoxyphenyl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]propan-2-ol Chemical compound COC1=CC=CC(C=2C=3N=NN(CC=4N=C(C=CC=4)C(C)(C)O)C=3N=C(N)N=2)=C1 WBQDITDDICQDQQ-UHFFFAOYSA-N 0.000 claims description 2
- YQYKENUCSZTMJE-UHFFFAOYSA-N 2-[6-[[5-amino-7-(4-methyl-1,3-thiazol-2-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]propan-2-ol Chemical compound CC1=CSC(C=2C=3N=NN(CC=4N=C(C=CC=4)C(C)(C)O)C=3N=C(N)N=2)=N1 YQYKENUCSZTMJE-UHFFFAOYSA-N 0.000 claims description 2
- XPZYUVLLSFGKPS-UHFFFAOYSA-N 2-[6-[[5-amino-7-(5-methylfuran-2-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]propan-2-ol Chemical compound O1C(C)=CC=C1C1=NC(N)=NC2=C1N=NN2CC1=CC=CC(C(C)(C)O)=N1 XPZYUVLLSFGKPS-UHFFFAOYSA-N 0.000 claims description 2
- 125000000389 2-pyrrolyl group Chemical group [H]N1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- LLBYTELQINWZIJ-UHFFFAOYSA-N 3-[5-amino-3-[[6-(1-hydroxycyclobutyl)pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-7-yl]benzonitrile Chemical compound C=12N=NN(CC=3N=C(C=CC=3)C3(O)CCC3)C2=NC(N)=NC=1C1=CC=CC(C#N)=C1 LLBYTELQINWZIJ-UHFFFAOYSA-N 0.000 claims description 2
- ONCBSTLSMMBXHX-UHFFFAOYSA-N 3-[5-amino-3-[[6-(1-hydroxycyclopentyl)pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-7-yl]benzonitrile Chemical class C=12N=NN(CC=3N=C(C=CC=3)C3(O)CCCC3)C2=NC(N)=NC=1C1=CC=CC(C#N)=C1 ONCBSTLSMMBXHX-UHFFFAOYSA-N 0.000 claims description 2
- BCQRGFUTGJBNKT-UHFFFAOYSA-N 3-[5-amino-3-[[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-7-yl]benzonitrile Chemical compound CC(C)(O)C1=CC=CC(CN2C3=NC(N)=NC(=C3N=N2)C=2C=C(C=CC=2)C#N)=N1 BCQRGFUTGJBNKT-UHFFFAOYSA-N 0.000 claims description 2
- VAYVTDPINUWJKZ-UHFFFAOYSA-N 3-[5-amino-3-[[6-(4-hydroxyoxan-4-yl)pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-7-yl]benzonitrile Chemical compound C=12N=NN(CC=3N=C(C=CC=3)C3(O)CCOCC3)C2=NC(N)=NC=1C1=CC=CC(C#N)=C1 VAYVTDPINUWJKZ-UHFFFAOYSA-N 0.000 claims description 2
- IJPKWTVYFLHMFF-UHFFFAOYSA-N 3-[5-amino-3-[[6-(methoxymethyl)pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-7-yl]benzonitrile Chemical compound COCC1=CC=CC(CN2C3=NC(N)=NC(=C3N=N2)C=2C=C(C=CC=2)C#N)=N1 IJPKWTVYFLHMFF-UHFFFAOYSA-N 0.000 claims description 2
- ZOHVFUHFROEVQT-UHFFFAOYSA-N 3-[[6-(2-ethoxyethoxymethyl)pyridin-2-yl]methyl]-7-(5-methylfuran-2-yl)triazolo[4,5-d]pyrimidin-5-amine Chemical compound CCOCCOCC1=CC=CC(CN2C3=NC(N)=NC(=C3N=N2)C=2OC(C)=CC=2)=N1 ZOHVFUHFROEVQT-UHFFFAOYSA-N 0.000 claims description 2
- WYPAOIKIACVSIU-UHFFFAOYSA-N 3-[[6-(2-methoxypropan-2-yloxymethyl)pyridin-2-yl]methyl]-7-(5-methylfuran-2-yl)triazolo[4,5-d]pyrimidin-5-amine Chemical compound COC(C)(C)OCC1=CC=CC(CN2C3=NC(N)=NC(=C3N=N2)C=2OC(C)=CC=2)=N1 WYPAOIKIACVSIU-UHFFFAOYSA-N 0.000 claims description 2
- UXNXXNBJQBWBBC-UHFFFAOYSA-N 3-[[6-(difluoromethoxymethyl)pyridin-2-yl]methyl]-7-(5-methylfuran-2-yl)triazolo[4,5-d]pyrimidin-5-amine Chemical compound O1C(C)=CC=C1C1=NC(N)=NC2=C1N=NN2CC1=CC=CC(COC(F)F)=N1 UXNXXNBJQBWBBC-UHFFFAOYSA-N 0.000 claims description 2
- UESWRCOBJTWHIX-UHFFFAOYSA-N 3-[[6-(methoxymethyl)pyridin-2-yl]methyl]-7-(3-methoxyphenyl)triazolo[4,5-d]pyrimidin-5-amine Chemical compound COCC1=CC=CC(CN2C3=NC(N)=NC(=C3N=N2)C=2C=C(OC)C=CC=2)=N1 UESWRCOBJTWHIX-UHFFFAOYSA-N 0.000 claims description 2
- LZJBVOMKJQWHML-UHFFFAOYSA-N 3-[[6-(methoxymethyl)pyridin-2-yl]methyl]-7-phenyltriazolo[4,5-d]pyrimidin-5-amine Chemical compound COCC1=CC=CC(CN2C3=NC(N)=NC(=C3N=N2)C=2C=CC=CC=2)=N1 LZJBVOMKJQWHML-UHFFFAOYSA-N 0.000 claims description 2
- YNRLREZIGIVCIG-UHFFFAOYSA-N 4-[6-[(5-amino-7-phenyltriazolo[4,5-d]pyrimidin-3-yl)methyl]pyridin-2-yl]oxan-4-ol Chemical compound C=12N=NN(CC=3N=C(C=CC=3)C3(O)CCOCC3)C2=NC(N)=NC=1C1=CC=CC=C1 YNRLREZIGIVCIG-UHFFFAOYSA-N 0.000 claims description 2
- DLIYMAPNSDNKEQ-UHFFFAOYSA-N 4-[6-[[5-amino-7-(3-methoxyphenyl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]oxan-4-ol Chemical compound COC1=CC=CC(C=2C=3N=NN(CC=4N=C(C=CC=4)C4(O)CCOCC4)C=3N=C(N)N=2)=C1 DLIYMAPNSDNKEQ-UHFFFAOYSA-N 0.000 claims description 2
- JHHCMMVKLXZUPL-UHFFFAOYSA-N 4-[6-[[5-amino-7-(4-methyl-1,3-thiazol-2-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]oxan-4-ol Chemical compound CC1=CSC(C=2C=3N=NN(CC=4N=C(C=CC=4)C4(O)CCOCC4)C=3N=C(N)N=2)=N1 JHHCMMVKLXZUPL-UHFFFAOYSA-N 0.000 claims description 2
- COENJCHOYLKDNG-UHFFFAOYSA-N 4-[6-[[5-amino-7-(5-methylfuran-2-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]oxan-4-ol Chemical compound O1C(C)=CC=C1C1=NC(N)=NC2=C1N=NN2CC1=CC=CC(C2(O)CCOCC2)=N1 COENJCHOYLKDNG-UHFFFAOYSA-N 0.000 claims description 2
- QOASHFYQMZOHPI-UHFFFAOYSA-N 7-(5-methylfuran-2-yl)-3-[[6-(2,2,2-trifluoroethoxymethyl)pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine Chemical compound O1C(C)=CC=C1C1=NC(N)=NC2=C1N=NN2CC1=CC=CC(COCC(F)(F)F)=N1 QOASHFYQMZOHPI-UHFFFAOYSA-N 0.000 claims description 2
- XPZHJACMHBMAMG-UHFFFAOYSA-N 7-(5-methylfuran-2-yl)-3-[[6-(2-propan-2-yloxyethylperoxymethyl)pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine Chemical compound CC1=CC=C(O1)C=1C2=C(N=C(N=1)N)N(N=N2)CC1=NC(=CC=C1)COOCCOC(C)C XPZHJACMHBMAMG-UHFFFAOYSA-N 0.000 claims description 2
- KCILAWKAHWFBDN-UHFFFAOYSA-N 7-(5-methylfuran-2-yl)-3-[[6-(oxolan-2-ylmethoxymethyl)pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine Chemical compound O1C(C)=CC=C1C1=NC(N)=NC2=C1N=NN2CC1=CC=CC(COCC2OCCC2)=N1 KCILAWKAHWFBDN-UHFFFAOYSA-N 0.000 claims description 2
- VEDXQMZUZASSKU-UHFFFAOYSA-N 7-(5-methylfuran-2-yl)-3-[[6-(oxolan-3-ylmethoxymethyl)pyridin-2-yl]methyl]triazolo[4,5-d]pyrimidin-5-amine Chemical compound O1C(C)=CC=C1C1=NC(N)=NC2=C1N=NN2CC1=CC=CC(COCC2COCC2)=N1 VEDXQMZUZASSKU-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 11
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000001149 cognitive effect Effects 0.000 claims 2
- NNIXXMBWAIAPPE-UHFFFAOYSA-N 1-[6-[[5-amino-7-(4-methyl-1,3-thiazol-2-yl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]cyclobutan-1-ol Chemical compound CC1=CSC(C=2C=3N=NN(CC=4N=C(C=CC=4)C4(O)CCC4)C=3N=C(N)N=2)=N1 NNIXXMBWAIAPPE-UHFFFAOYSA-N 0.000 claims 1
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940127557 pharmaceutical product Drugs 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- XPQLAYQODILNNG-UHFFFAOYSA-N 1-[6-[[5-amino-7-(3-methoxyphenyl)triazolo[4,5-d]pyrimidin-3-yl]methyl]pyridin-2-yl]cyclopentan-1-ol Chemical class COC1=CC=CC(C=2C=3N=NN(CC=4N=C(C=CC=4)C4(O)CCCC4)C=3N=C(N)N=2)=C1 XPQLAYQODILNNG-UHFFFAOYSA-N 0.000 description 1
- 102000009346 Adenosine receptors Human genes 0.000 description 1
- 108050000203 Adenosine receptors Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 239000002467 adenosine A2a receptor antagonist Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7553808P | 2008-06-25 | 2008-06-25 | |
| US61/075,538 | 2008-06-25 | ||
| GBGB0906579.8A GB0906579D0 (en) | 2009-04-16 | 2009-04-16 | Pharmaceuticals, compositions and methods of making and using the same |
| GB0906579.8 | 2009-04-16 | ||
| PCT/GB2009/001605 WO2009156737A1 (en) | 2008-06-25 | 2009-06-25 | Triazolo [4, 5-d] pyramidine derivatives and their use as purine receptor antagonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011525898A JP2011525898A (ja) | 2011-09-29 |
| JP2011525898A5 true JP2011525898A5 (cg-RX-API-DMAC7.html) | 2013-04-11 |
| JP5559162B2 JP5559162B2 (ja) | 2014-07-23 |
Family
ID=40750727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011515594A Active JP5559162B2 (ja) | 2008-06-25 | 2009-06-25 | プリン受容体アンタゴニストとしてのトリアゾロ［４，５−ｄ］ピリミジン誘導体およびその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (9) | US8450328B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2321321B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5559162B2 (cg-RX-API-DMAC7.html) |
| KR (3) | KR102008640B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN102076692B (cg-RX-API-DMAC7.html) |
| AT (1) | ATE544767T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009263976B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0910182B8 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2727444C (cg-RX-API-DMAC7.html) |
| DK (1) | DK2321321T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA018803B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2382154T3 (cg-RX-API-DMAC7.html) |
| GB (1) | GB0906579D0 (cg-RX-API-DMAC7.html) |
| IL (2) | IL210071A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2010013841A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ590590A (cg-RX-API-DMAC7.html) |
| PL (1) | PL2321321T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2321321E (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009156737A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201100526B (cg-RX-API-DMAC7.html) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
| CA2755117C (en) | 2009-03-13 | 2018-09-11 | Advinus Therapeutics Private Limited | Substituted fused pyrimidine compounds |
| WO2011101861A1 (en) | 2010-01-29 | 2011-08-25 | Msn Laboratories Limited | Process for preparation of dpp-iv inhibitors |
| CA2869535A1 (en) * | 2012-05-30 | 2013-12-05 | F. Hoffmann-La Roche Ag | Pyrrolidino heterocycles |
| US10781178B2 (en) | 2015-08-12 | 2020-09-22 | The General Hospital Corporation | 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents |
| US10912776B2 (en) | 2015-12-24 | 2021-02-09 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
| US10793636B2 (en) | 2016-07-11 | 2020-10-06 | Corvus Pharmaceuticals, Inc. | Anti-CD73 antibodies |
| KR20190104529A (ko) | 2016-12-03 | 2019-09-10 | 주노 쎄러퓨티크스 인코퍼레이티드 | Car-t 세포의 조절 방법 |
| EP4279136A3 (en) | 2016-12-03 | 2024-03-20 | Juno Therapeutics, Inc. | Methods for determining car-t cells dosing |
| SG11201905812WA (en) * | 2017-01-20 | 2019-08-27 | Arcus Biosciences Inc | Azolopyrimidine for the treatment of cancer-related disorders |
| US10654825B2 (en) * | 2017-03-30 | 2020-05-19 | Corvus Pharmaceuticals, Inc. | Processes for making triazolo[4,5D] pyramidine derivatives and intermediates thereof |
| WO2018187508A1 (en) * | 2017-04-04 | 2018-10-11 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
| US11040040B2 (en) | 2017-04-04 | 2021-06-22 | Corvus Pharmaceuticals, Inc. | Methods of treating cancer |
| AU2018250336B2 (en) | 2017-04-07 | 2025-02-20 | Juno Therapeutics, Inc. | Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods |
| US11413310B2 (en) | 2017-06-02 | 2022-08-16 | Juno Therapeutics, Inc. | Articles of manufacture and methods for treatment using adoptive cell therapy |
| CN110785187B (zh) | 2017-06-22 | 2024-04-05 | 诺华股份有限公司 | 针对cd73的抗体分子及其用途 |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| WO2019006427A1 (en) | 2017-06-29 | 2019-01-03 | Juno Therapeutics, Inc. | WALL MODEL FOR ASSESSING TOXICITIES ASSOCIATED WITH IMMUNOTHERAPIES |
| BR112020008638A2 (pt) | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma) |
| US12031975B2 (en) | 2017-11-01 | 2024-07-09 | Juno Therapeutics, Inc. | Methods of assessing or monitoring a response to a cell therapy |
| MA49911A (fr) | 2017-11-01 | 2020-06-24 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b |
| JP2021502342A (ja) * | 2017-11-06 | 2021-01-28 | コーバス・ファーマシューティカルズ・インコーポレイテッド | 癌処置のためのアデノシン経路阻害剤 |
| MX2020004756A (es) | 2017-11-16 | 2020-08-20 | Novartis Ag | Terapias de combinacion. |
| AU2018375738A1 (en) | 2017-11-30 | 2020-06-11 | Novartis Ag | BCMA-targeting chimeric antigen receptor, and uses thereof |
| US20210198372A1 (en) | 2017-12-01 | 2021-07-01 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
| MA51184A (fr) | 2017-12-15 | 2020-10-21 | Juno Therapeutics Inc | Molécules de liaison à l'anti-cct5 et procédés d'utilisation associés |
| MX2020007559A (es) * | 2018-02-01 | 2020-09-03 | Corvus Pharmaceuticals Inc | Formulaciones farmaceuticas. |
| US20190231783A1 (en) | 2018-02-01 | 2019-08-01 | Corvus Pharmaceuticals, Inc. | Pharmaceutical formulations |
| CN111511745B (zh) * | 2018-02-06 | 2022-05-27 | 江苏恒瑞医药股份有限公司 | 吡唑并[1，5-a][1，3，5]三嗪-2-胺类衍生物、其制备方法及其应用 |
| MA51875A (fr) | 2018-02-13 | 2020-12-23 | Iovance Biotherapeutics Inc | Expansion de lymphocytes infiltrant les tumeurs (til) avec des antagonistes du récepteur a2a de l'adénosine et combinaisons thérapeutiques de til et d'antagonistes du récepteur a2a de l'adénosine |
| US10738128B2 (en) | 2018-03-14 | 2020-08-11 | Surface Oncology, Inc. | Antibodies that bind CD39 and uses thereof |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| US20210214459A1 (en) | 2018-05-31 | 2021-07-15 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| BR112020024351A2 (pt) | 2018-06-01 | 2021-02-23 | Novartis Ag | moléculas de ligação contra bcma e usos das mesmas |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| CA3106038A1 (en) | 2018-07-12 | 2020-01-16 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| CA3106041A1 (en) | 2018-07-12 | 2020-01-16 | Corvus Pharmaceuticals, Inc. | Methods for detecting and treating cancers having adenosine pathway activation |
| US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
| IL281802B2 (en) | 2018-09-27 | 2025-10-01 | iTeos Belgium SA | Use of an ENT family transporter inhibitor in cancer treatment and its combination with an adenosine receptor antagonist |
| BE1026612B1 (fr) | 2018-09-27 | 2020-07-02 | Iteos Therapeutics S A | Utilisation d’un inhibiteur d’un transporteur de la famille ent dans le traitement du cancer et combinaison de celui-ci avec un antagoniste de recepteur de l’adenosine |
| WO2020068583A1 (en) * | 2018-09-27 | 2020-04-02 | Corvus Pharmaceuticals, Inc. | Processes for making triazolo [4,5d] pyramidine derivatives and intermediates thereof |
| SG11202104188VA (en) | 2018-11-01 | 2021-05-28 | Juno Therapeutics Inc | Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen |
| TW202021981A (zh) | 2018-11-01 | 2020-06-16 | 美商奇諾治療有限公司 | G蛋白偶合受體c類第5群成員d（gprc5d）特異性嵌合抗原受體 |
| BR112021009420A2 (pt) | 2018-11-16 | 2021-11-23 | Juno Therapeutics Inc | Métodos de dosagem de células t manipuladas para o tratamento de malignidades de células b |
| US12466831B2 (en) * | 2018-11-20 | 2025-11-11 | Merck Sharp & Dohme Llc | Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use |
| EP3886875B1 (en) | 2018-11-30 | 2024-05-08 | Juno Therapeutics, Inc. | Methods for treatment using adoptive cell therapy |
| BR112021011874A2 (pt) | 2018-12-20 | 2021-09-08 | Novartis Ag | Regime de dosagem e combinação farmacêutica compreendendo derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona |
| MA54863A (fr) | 2019-01-29 | 2021-12-08 | Juno Therapeutics Inc | Anticorps et récepteurs antigéniques chimériques spécifiques du récepteur orphelin-1 de type récepteur à tyrosine kinase (ror1) |
| AU2020222346B2 (en) | 2019-02-15 | 2021-12-09 | Novartis Ag | Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2020165833A1 (en) | 2019-02-15 | 2020-08-20 | Novartis Ag | 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US11655303B2 (en) | 2019-09-16 | 2023-05-23 | Surface Oncology, Inc. | Anti-CD39 antibody compositions and methods |
| TW202124446A (zh) | 2019-09-18 | 2021-07-01 | 瑞士商諾華公司 | 與ｅｎｔｐｄ２抗體之組合療法 |
| JP2022548881A (ja) | 2019-09-18 | 2022-11-22 | ノバルティス アーゲー | Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法 |
| TW202521984A (zh) | 2019-09-25 | 2025-06-01 | 美商表面腫瘤學有限責任公司 | 抗ｉｌ－２７抗體及其用途 |
| KR20210061202A (ko) * | 2019-11-19 | 2021-05-27 | 일동제약(주) | 벤조나이트릴이 치환된 축합 피리미딘 유도체 및 그의 의약 용도 |
| CN115175937A (zh) | 2019-12-20 | 2022-10-11 | 诺华股份有限公司 | 用于治疗骨髓纤维化和骨髓增生异常综合征的抗TIM-3抗体MBG453和抗TGF-β抗体NIS793与或不与地西他滨或抗PD-1抗体斯巴达珠单抗的组合 |
| US20230089247A1 (en) * | 2019-12-24 | 2023-03-23 | Zydus Lifesciences Limited | Novel compounds suitable for the treatment of dyslipidemia |
| CN115996927A (zh) | 2020-02-26 | 2023-04-21 | Iteos比利时公司 | 作为ENT抑制剂用于治疗癌症的嘧啶并[5,4-d]嘧啶衍生物及其与腺苷受体拮抗剂的组合 |
| US20230203058A1 (en) | 2020-04-07 | 2023-06-29 | iTeos Belgium SA | Macrocyclic diamine derivatives as ent inhibitors for the treatment of cancers, and combination thereof with adenosine receptor antagonists |
| WO2021207689A2 (en) | 2020-04-10 | 2021-10-14 | Juno Therapeutics, Inc. | Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen |
| CA3182346A1 (en) | 2020-06-23 | 2021-12-30 | Novartis Ag | Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| US20230271940A1 (en) | 2020-08-03 | 2023-08-31 | Novartis Ag | Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| US20240025993A1 (en) | 2020-11-06 | 2024-01-25 | Novartis Ag | Cd19 binding molecules and uses thereof |
| JP2024505049A (ja) | 2021-01-29 | 2024-02-02 | ノバルティス アーゲー | 抗ｃｄ７３及び抗ｅｎｔｐｄ２抗体のための投与方式並びにその使用 |
| WO2022178135A1 (en) | 2021-02-17 | 2022-08-25 | Iteos Belguim Sa | Compounds, compositions and methods of treatment thereof |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
| EP4543923A1 (en) | 2022-06-22 | 2025-04-30 | Juno Therapeutics, Inc. | Treatment methods for second line therapy of cd19-targeted car t cells |
| WO2024031091A2 (en) | 2022-08-05 | 2024-02-08 | Juno Therapeutics, Inc. | Chimeric antigen receptors specific for gprc5d and bcma |
| AR131320A1 (es) | 2022-12-13 | 2025-03-05 | Juno Therapeutics Inc | Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos |
| WO2024134541A1 (en) | 2022-12-20 | 2024-06-27 | iTeos Belgium SA | Heterocyclic compounds as ent inhibitors and compounds for use in the treatment of cancers |
| WO2025104613A1 (en) | 2023-11-14 | 2025-05-22 | iTeos Belgium SA | Ent1 inhibitors in combination with checkpoint inhibitors |
| KR20250123663A (ko) * | 2024-02-08 | 2025-08-18 | 아이리드비엠에스 주식회사 | Cxcr7 수용체 조절제 및 이의 용도 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS56131586A (en) | 1980-03-18 | 1981-10-15 | Ss Pharmaceut Co Ltd | Triazolopyrimidine derivative and its preparation |
| JPS56131587A (en) | 1980-03-18 | 1981-10-15 | Ss Pharmaceut Co Ltd | 7-substituted triazolopyrimidine derivative and its preparation |
| JPS5962595A (ja) | 1982-09-30 | 1984-04-10 | Ss Pharmaceut Co Ltd | ３，５，７―トリ置換―トリアゾロピリミジン誘導体 |
| DE3304330A1 (de) | 1983-02-09 | 1984-08-09 | Basf Ag, 6700 Ludwigshafen | Neue 2h-v-triazolyl(4,5-d)-pyrimidine und deren verwendung |
| JPS60140335A (ja) | 1983-12-28 | 1985-07-25 | Konishiroku Photo Ind Co Ltd | 熱現像カラ−感光材料 |
| US5204353A (en) | 1987-04-07 | 1993-04-20 | Ciba-Geigy Corporation | 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith |
| AU692484B2 (en) | 1993-10-12 | 1998-06-11 | Du Pont Pharmaceuticals Company | 1N-alkyl-N-arylpyrimidinamines and derivatives thereof |
| JP4084415B2 (ja) | 1995-07-11 | 2008-04-30 | アストラゼネカ・アクチエボラーグ | 新しい血小板凝集抑制剤 |
| ZA971896B (en) | 1996-03-26 | 1998-09-07 | Du Pont Merck Pharma | Aryloxy-and arythio-fused pyridines and pyrimidines and derivatives |
| JP3621706B2 (ja) | 1996-08-28 | 2005-02-16 | ファイザー・インク | 置換された６，５―ヘテロ―二環式誘導体 |
| CA2296014A1 (en) | 1997-07-03 | 1999-01-14 | Frank W. Hobbs | Aryl-and arylamino-substituted heterocycles as corticotropin releasing hormone antagonists |
| DE19736535C1 (de) | 1997-08-22 | 1999-01-28 | Basf Coatings Ag | Basislackzusammensetzung sowie Verfahren zur Herstellung von mehrschichtigen Überzügen |
| US5939432A (en) | 1997-10-29 | 1999-08-17 | Medco Research, Inc. | Thiophenes useful for modulating the adenosine receptor |
| WO1999026627A1 (en) | 1997-11-26 | 1999-06-03 | Cerebrus Limited | (-)-mefloquine to block purinergic receptors and to treat movement or neurodegenerative disorders |
| EP1300147A1 (en) | 1998-01-05 | 2003-04-09 | Eisai Co. Ltd | Purine compounds and adenosine A2 receptor antagonist as preventive or therapeutic agent for diabetes mellitus |
| US6326390B1 (en) | 1998-08-25 | 2001-12-04 | King Pharmaceuticals Reseach And Development, Inc. | Use of adenosine A3 receptor antagonists to inhibit tumor growth |
| GB9819384D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds II |
| GB9819382D0 (en) | 1998-09-04 | 1998-10-28 | Cerebrus Ltd | Chemical compounds I |
| GB9915437D0 (en) | 1999-07-01 | 1999-09-01 | Cerebrus Ltd | Chemical compounds III |
| JP4324338B2 (ja) | 1999-07-02 | 2009-09-02 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 縮合イミダゾール化合物及び糖尿病治療薬 |
| GB0100623D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds IV |
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| WO2007125321A2 (en) * | 2006-04-25 | 2007-11-08 | Astex Therapeutics Limited | Purine and deazapurine derivatives as pharmaceutical compounds |
| GB0906579D0 (en) * | 2009-04-16 | 2009-05-20 | Vernalis R&D Ltd | Pharmaceuticals, compositions and methods of making and using the same |
-
2009
- 2009-04-16 GB GBGB0906579.8A patent/GB0906579D0/en not_active Ceased
- 2009-06-25 KR KR1020187031734A patent/KR102008640B1/ko active Active
- 2009-06-25 MX MX2010013841A patent/MX2010013841A/es active IP Right Grant
- 2009-06-25 WO PCT/GB2009/001605 patent/WO2009156737A1/en not_active Ceased
- 2009-06-25 BR BRPI0910182A patent/BRPI0910182B8/pt active IP Right Grant
- 2009-06-25 US US12/997,721 patent/US8450328B2/en active Active
- 2009-06-25 CN CN200980124230.6A patent/CN102076692B/zh active Active
- 2009-06-25 PL PL09769578T patent/PL2321321T3/pl unknown
- 2009-06-25 KR KR1020167026831A patent/KR20160116054A/ko not_active Ceased
- 2009-06-25 EP EP09769578A patent/EP2321321B1/en active Active
- 2009-06-25 JP JP2011515594A patent/JP5559162B2/ja active Active
- 2009-06-25 PT PT09769578T patent/PT2321321E/pt unknown
- 2009-06-25 EA EA201100079A patent/EA018803B1/ru not_active IP Right Cessation
- 2009-06-25 AT AT09769578T patent/ATE544767T1/de active
- 2009-06-25 NZ NZ590590A patent/NZ590590A/en unknown
- 2009-06-25 DK DK09769578.7T patent/DK2321321T3/da active
- 2009-06-25 AU AU2009263976A patent/AU2009263976B2/en active Active
- 2009-06-25 ES ES09769578T patent/ES2382154T3/es active Active
- 2009-06-25 CA CA2727444A patent/CA2727444C/en active Active
- 2009-06-25 KR KR1020117001954A patent/KR101680390B1/ko active Active
-
2010
- 2010-12-16 IL IL210071A patent/IL210071A/en active IP Right Grant
-
2011
- 2011-01-20 ZA ZA2011/00526A patent/ZA201100526B/en unknown
-
2013
- 2013-05-08 US US13/889,921 patent/US8987279B2/en active Active
-
2015
- 2015-02-10 US US14/618,829 patent/US9376443B2/en active Active
-
2016
- 2016-01-11 IL IL243574A patent/IL243574B/en active IP Right Grant
- 2016-06-02 US US15/172,126 patent/US9765080B2/en active Active
-
2017
- 2017-08-21 US US15/682,346 patent/US10106547B2/en active Active
-
2018
- 2018-09-15 US US16/132,411 patent/US10538526B2/en active Active
-
2019
- 2019-12-02 US US16/700,160 patent/US10875868B2/en active Active
-
2020
- 2020-11-03 US US17/088,325 patent/US11466019B2/en active Active
-
2022
- 2022-08-24 US US17/895,037 patent/US20230100842A1/en not_active Abandoned